title: Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
abstract: BACKGROUND
  Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer.
  
  
  METHODS
  Lapatinib was tested against the cell lines of the PPTP in vitro panel at concentrations ranging from 1.0 nM to 10.0 microM. Lapatinib was tested against the xenografts of the PPTP in vivo panels using a twice-daily oral administration schedule for 6 weeks (5 days on, 2 days off) at a dose of 160 mg/kg (320 mg/kg/day). Lapatinib pharmacokinetic parameters were determined in scid(-/-) mice.
  
  
  RESULTS
  The median IC(50) value for lapatinib against the entire PPTP cell line panel was 6.84 microM (range, 2.08 to >10.0 microM). Lapatinib was well tolerated in vivo, with toxicity in only 1.5% of the treated animals. Lapatinib induced significant differences in EFS distribution compared to controls in 1 of 41 xenografts tested. No objective responses were observed in any of the solid tumor panels or in the ALL panel. Lapatinib systemic exposure was consistent with previously observed values.
  
  
  CONCLUSIONS
  Lapatinib has little activity against the xenografts of the PPTP's in vivo panel, and its in vitro activity occurs at concentrations above those associated with specific EGFR/ErbB2 inhibition. These results likely reflect lack of ErbB2 overexpression in the models studied and suggest that adult and pediatric cancers may fundamentally differ in the applicability of EGFR family members as therapeutic targets.
authors: The Children's Hospital at Montefiore, Bronx, New York 10467, USA.
authors: Richard
authors: R
authors: Gorlick
authors: E Anders
authors: EA
authors: Kolb
authors: Peter J
authors: PJ
authors: Houghton
authors: Christopher L
authors: CL
authors: Morton
authors: Doris
authors: D
authors: Phelps
authors: Paula
authors: P
authors: Schaiquevich
authors: Clinton
authors: C
authors: Stewart
authors: Stephen T
authors: ST
authors: Keir
authors: Richard
authors: R
authors: Lock
authors: Hernan
authors: H
authors: Carol
authors: C Patrick
authors: CP
authors: Reynolds
authors: John M
authors: JM
authors: Maris
authors: Jianrong
authors: J
authors: Wu
authors: Malcolm A
authors: MA
authors: Smith
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D004354:Drug Screening Assays, Antitumor; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D000077341:Lapatinib; D051379:Mice; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011799:Quinazolines / Q000493:pharmacokinetics / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases